Jump to content

Drilldown: Medicines

Choose a table:


Medicines > generic : 1cP-LSD or 2C-B or Methotrexate

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
None (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Trexall, Otrexup, Rasuvo, Xatmep, Rheumatrex (discontinued) (1)
classes:
2C-x series (1) · Classic Psychedelic (1) · Lysergamide (1) · Phenethylamine (1) · Psychedelic (1) · Research material (1) · [[:Category:Antifolates|Antifolate]] (1) · [[:Category:Antineoplastics|Antineoplastic]] (1) · [[:Category:DMARDs|DMARD]] (1) · [[:Category:Immunosuppressants|Immunosuppressant]] (1)
mechanism:
None (1) · 5-HT2A partial agonist (1) · Prodrug of LSD; 5-HT2A agonist (1)
uses:
None (2) · '"`UNIQ--vote-000007C1-QINU`"', '"`UNIQ--vote-000007C2-QINU`"', '"`UNIQ--vote-000007C3-QINU`"', '"`UNIQ--vote-000007C4-QINU`"', '"`UNIQ--vote-000007C5-QINU`"', '"`UNIQ--vote-000007C6-QINU`"', '"`UNIQ--vote-000007C7-QINU`"' (1)
starting dose:
None (2) · Rheumatologic: 7.5-15 mg PO or SC '''once weekly''' (not daily — daily dosing is a recognized fatal error); folic acid 1 mg PO daily on non-MTX days; oncology dosing is far higher and indication-specific (1)
preparations:
None (2) · 2.5 mg tablets; 10-50 mg/mL injection; pre-filled subcutaneous autoinjectors (Otrexup, Rasuvo); 2.5 mg/mL oral solution (Xatmep) (1)
fda max:
None (2) · Rheumatologic ~25 mg/week; oncology indication-specific (1)
routes:
None (1) · insufflated (1) · intramuscular (1) · intrathecal (1) · IV (1) · Oral (2) · PR (1) · subcutaneous (1)
onset:
None (1) · 45-75 min (oral) (1) · Rheumatologic effect at 4-8 weeks; ectopic resolution over 2-3 weeks (1)
duration:
None (1) · 4-8 h (1) · Once-weekly dosing in rheumatology (1)
halflife:
None (1) · 3-10 hours (low dose); 8-15 hours (high dose); much longer in third-space accumulation (pleural effusion, ascites)'"`UNIQ--ref-000007C8-QINU`"' (1) · Not well characterized (1)
bioavailability:
None (1) · 60-70% PO at low doses; saturable at high doses (parenteral routes preferred above 15-25 mg/week)'"`UNIQ--ref-000007C9-QINU`"' (1) · Not well characterized (1)
pregnancy:
None (1) · '''Contraindicated in pregnancy''' (Category X); abortifacient and teratogenic. Discontinuation 3-6 months before conception is standard.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (1)
legal:
None (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (1)

Showing below up to 3 results in range #1 to #3.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

2


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"